Moderna has paid $400 million to the government for a chemical technique key to its vaccine.
Health & Wellness:
As part of the agreement with the NIH, Moderna will pay the agency $400 million in royalties for the use of its patented technology.
The payout is a result of the NIH's investment in the development of the vaccine, as well as its contribution to the underlying technology used in the vaccine.
The agreement also includes provisions for future collaboration between Moderna and the NIH on research and development of vaccines and therapies.
Moderna also received nearly $10 billion in taxpayer funding to develop and test the vaccine, and to provide doses to the federal government.